Company profile: AbbVie
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies and precision medicine across immunology, oncology, neuroscience, virology, and aesthetics. Offers HUMIRA for autoimmune conditions, IMBRUVICA for certain cancers, and RINVOQ for inflammatory diseases. Delivers genomics research and the AbbVie R&D Convergence Hub (ARCH) to integrate data and advance personalized drug discovery and treatment insights.
Products and services
- IMBRUVICA: Treats certain cancers, including chronic lymphocytic leukemia and mantle cell lymphoma
- Oncology-focused therapeutic for hematologic malignancies
- RINVOQ: Treats rheumatoid arthritis and other inflammatory conditions in immunology
- Immunology-targeted medication used across inflammation-related indications
- HUMIRA: Treats various autoimmune conditions by reducing inflammation in immunology
- Immunology-focused therapeutic applicable across multiple autoimmune indications
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to AbbVie
Lilly
HQ: United States
Website
- Description: Provider of medicines for diabetes, cancer, immunology, and other major health areas, including insulin products with affordability initiatives ($35 or less/month); Efsitora for type 2 diabetes via autoinjector; EBGLYSS for moderate-to-severe atopic dermatitis; Jaypirca for relapsed/refractory MCL and CLL/SLL; Zepbound (tirzepatide) for obesity; Verzenio for HR+, HER2- early breast cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lilly company profile →
Cullgen
HQ: United States
Website
- Description: Provider of drug discovery services leveraging its uSMITE platform to develop targeted protein degraders using novel E3 ligands for diseases lacking effective therapies, including cancer, inflammation, autoimmune, and neurodegenerative disorders; pipeline includes CG001419, an orally bioavailable pan-TRK degrader in phase I/II clinical trial for solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cullgen company profile →
Labopharm
HQ: Canada
Website
- Description: Provider of specialty pharmaceutical solutions that optimize the performance of existing drugs using advanced controlled-release technologies; operates internationally.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Labopharm company profile →
Chronos Therapeutics
HQ: United Kingdom
Website
- Description: Provider of age-related disease drug development, advancing SFX-01, a sulforaphane-based stable tablet for oncology and neurodevelopmental disorders; a highly selective orexin 1 receptor antagonist for addictive behaviors including binge eating disorder and alcohol use disorder; and an atypical DAT inhibitor for fatigue and narcolepsy, plus licensing and partnership collaborations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Chronos Therapeutics company profile →
GlycoEra
HQ: Switzerland
Website
- Description: Provider of extracellular protein degraders for autoimmune diseases, leveraging its CustomGlycan platform to design bi-functional biologics that selectively degrade circulating or membrane disease-causing proteins, such as autoantibodies, without broadly suppressing the immune system. Offerings include G-LyTACs, a custom glycan engineering platform, and protein degradation therapeutics with applications in oncology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GlycoEra company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for AbbVie
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to AbbVie
2.2 - Growth funds investing in similar companies to AbbVie
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for AbbVie
4.2 - Public trading comparable groups for AbbVie
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →